United Kingdom
At GSK, we prevent and treat disease with specialty medicines, vaccines and general medicines.
We're a focused biopharma company with strong momentum and big ambitions. We're pursuing research and development across four core therapeutic areas: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases.
At GSK, we're dedicated to delivering a healthier future for the UK. We combine cutting-edge research, strategic partnerships, and large-scale delivery to transform healthcare, moving from treating symptoms to proactive prevention. Our commitment is to drive a prevention-led approach that benefits patients, the NHS, society, and our people. With over 35 million packs of GSK medicines and vaccines reaching UK patients each year, and a focus on areas like respiratory health and immunisation, we're putting patients back in control of their health and working towards positively impacting 2.5 billion people globally by the end of the decade.
We proudly support the NHS's shift from 'sickness to prevention', aiming to reduce illness and free up frontline capacity. As one of the UK’s largest pharmaceutical employers, with approximately 10,000 employees across nine sites, GSK is deeply invested in the country's long-term success. We're strengthening the UK's workforce and economy through significant investment in research and development, including over £1.5 billion annually in UK R&D and a £400 million investment to establish our new global R&D headquarters in Cambridge. Our collaborations across over 100 hospital trusts and health boards highlight our belief that a healthier future for the UK is a shared endeavour. To find out more, download our latest report.
Members of the public in the UK can obtain information about our products and areas of therapy by visiting our
Our locations in the UK
Contact details
GSK HQ
79 New Oxford Street
London
United Kingdom
WC1A 1DG
Healthcare professionals
Healthcare professionals (HCPs) in the UK can get information about our products and therapy areas by visiting GSKPro
As a healthcare company we regularly work with HCPs. From collaborating on clinical trials to providing high quality, balanced information about our medicines and vaccines, in all of our interactions we aim to be transparent about our work, operate with integrity, and always put the interests of patients first.
UK patient organisations
Patient organisations engage with healthcare providers, governments, the media, and patients to promote improved treatment and services for patients. They also campaign on issues that affect patients’ and care-givers’ lives, including increasing access to quality medicines, services and information on disease. Some carry out research into the causes of and potential treatments for specific conditions.
In line with the EFPIA code and the ABPI code, we disclose funding we provide to UK patient organisations on an annual basis.
- 2025 Disclosure for Patient Organisations (PDF - 357.3KB)
- 2025 Patient Organisation Methodical Note (PDF - 90.5KB)
- 2024 Disclosure for Patient Organisations (PDF - 480.1KB)
- 2024 Patient Organisation Methodological Note (PDF - 106.7KB)
- 2023 Disclosure for Patient Organisations (PDF - 334.9KB)
- 2023 Patient Organisation Methodological Note (PDF - 106.8KB)
UK patients, journalists and members of public
In line with the ABPI code, we disclose payments for certain contracted services made to patients, journalists and members of the public in the UK, on an aggregate basis.
- 2025 Disclosure for Member of Public, Patients & Journalists (PDF - 237.6KB)
- 2025 EFPIA HCPO Methodological Note English (PDF - 208.6KB)
- 2024 Disclosure for Member of Public, Patients & Journalists (PDF - 82.2KB)
- 2024 EFPIA HCPO Methodological Note English (PDF - 112.1KB)
- 2023 Disclosure for Member of Public, Patients & Journalists (PDF - 193.2KB)
- 2023 EFPIA HCPO Methodological Note English (PDF - 149.2KB)
GSK-sponsored projects
Discover GSK-sponsored projects which explore healthcare challenges and opportunities. Here you will find relevant projects aimed at deepening understanding of key topics with the aim of helping to contribute towards improved patient outcomes.
Joint working
We are actively involved in a wide number of joint working projects with the NHS throughout the UK. By working together we aim to improve the management of different conditions, introduce greater efficiency and to achieve our ambition to unite science, technology and talent to get ahead of disease together.
The projects outlined below were undertaken over the last five years and, over this period, codes, regulations and laws governing the areas covered by the studies may have changed. When reading the documents please be assured that all projects followed the particular standards in force at the time even though these may have subsequently changed.
All of the featured case studies are intended to give an overview of the individual project including its background, the potential benefits for the patient, the NHS, GSK and any other stakeholders.
Grants and donations
We recognise a responsibility to support activities in our medical community, whether related to medical education where there is patient need and common scientific interest, professional societies’ initiatives, or assisting healthcare organisations and projects that promote other healthcare goals. In all of our interactions we aim to be transparent about our work, operate with integrity, and always put the interests of patients first.
Carbon reduction plan
In accordance with UK Cabinet Office standards, the attachment below is GSK’s Carbon Reduction Plan completed in accordance with PPN 06/21 and associated guidance and reporting standards for Carbon Reduction Plans.
